• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

作者信息

Johira Yusuke, Kawaoka Tomokazu, Kosaka Masanari, Shirane Yuki, Miura Ryoichi, Murakami Serami, Yano Shigeki, Amioka Kei, Naruto Kensuke, Ando Yuwa, Kosaka Yumi, Kodama Kenichiro, Uchikawa Shinsuke, Fujino Hatsue, Ono Atsushi, Nakahara Takashi, Murakami Eisuke, Okamoto Wataru, Yamauchi Masami, Imamura Michio, Sentani Kazuhiro, Oue Naohide, Arihiro Koji, Kuroda Shintaro, Kobayashi Tsuyoshi, Ohdan Hideki, Chayama Kazuaki, Aikata Hiroshi

机构信息

Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan.

Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

出版信息

Liver Cancer. 2021 Nov 15;11(2):174-177. doi: 10.1159/000520898. eCollection 2022 Apr.

DOI:10.1159/000520898
PMID:35634428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9109072/
Abstract
摘要

相似文献

1
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿特珠单抗联合贝伐单抗治疗不可切除肝细胞癌失败后，乐伐替尼治疗取得病理完全缓解
Liver Cancer. 2021 Nov 15;11(2):174-177. doi: 10.1159/000520898. eCollection 2022 Apr.
2
Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series.肝癌患者在使用乐伐替尼后接受阿替利珠单抗联合贝伐单抗治疗出现的甲状腺功能障碍：病例系列报道
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231164488. doi: 10.1177/2050313X231164488. eCollection 2023.
3
Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.评估钆塞酸增强磁共振成像肝胆期在预测乐伐替尼、阿替利珠单抗联合贝伐单抗对不可切除肝细胞癌治疗效果中的作用。
Cancers (Basel). 2022 Feb 6;14(3):827. doi: 10.3390/cancers14030827.
4
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
5
Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌是否优于仑伐替尼？一项匹配调整的间接比较。
Target Oncol. 2021 Mar;16(2):249-254. doi: 10.1007/s11523-021-00803-8. Epub 2021 Feb 27.
6
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.阿替利珠单抗联合贝伐单抗用于晚期肝细胞癌临床实践的初步经验
Cancer Diagn Progn. 2021 May 3;1(2):83-88. doi: 10.21873/cdp.10012. eCollection 2021 May-Jun.
7
Conversion to Curative Resection and Pathological Complete Response Following Targeted Therapies With Atezolizumab and Bevacizumab for Initially Unresectable Hepatocellular Carcinoma: A Case Report.阿替利珠单抗和贝伐单抗靶向治疗后初始不可切除肝细胞癌转化为根治性切除及病理完全缓解：一例报告
Cureus. 2023 Sep 13;15(9):e45176. doi: 10.7759/cureus.45176. eCollection 2023 Sep.
8
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
9
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
10
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗对比索拉非尼用于不可切除或转移性肝细胞癌患者的成本效果分析。
JAMA Netw Open. 2021 Apr 1;4(4):e214846. doi: 10.1001/jamanetworkopen.2021.4846.

引用本文的文献

1
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌后使用乐伐替尼的疗效和安全性
Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406.
2
Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.阿替利珠单抗联合贝伐珠单抗与仑伐替尼治疗晚期肝细胞癌的临床疗效和安全性：系统评价和荟萃分析。
Medicine (Baltimore). 2023 Jun 9;102(23):e33852. doi: 10.1097/MD.0000000000033852.

本文引用的文献

1
Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.EOB-MRI肝胆期等高强度不可切除肝细胞癌的特征及乐伐替尼治疗反应
Cancers (Basel). 2021 Jul 20;13(14):3633. doi: 10.3390/cancers13143633.
2
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.对于先前接受PD-1/PD-L1检查点阻断治疗失败的不可切除肝细胞癌患者，乐伐替尼治疗的探索性分析
Cancers (Basel). 2020 Oct 20;12(10):3048. doi: 10.3390/cancers12103048.
3
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.肿瘤成纤维细胞生长因子受体4水平可预测晚期肝细胞癌患者使用乐伐替尼的疗效。
Clin Transl Gastroenterol. 2020 May;11(5):e00179. doi: 10.14309/ctg.0000000000000179.
4
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis.肝细胞癌的治疗前异质性增强模式可能是乐伐替尼早期反应和总体预后的一种有用的新预测指标。
Liver Cancer. 2020 Jun;9(3):275-292. doi: 10.1159/000505190. Epub 2020 Feb 4.
5
OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma.OATP1B3 表达与 Wnt/β-连环蛋白信号通路密切相关，是肝癌中钆塞酸的转运体。
J Hepatol. 2014 Nov;61(5):1080-7. doi: 10.1016/j.jhep.2014.06.008. Epub 2014 Jun 16.